The import value of vaccines for human use to China is forecasted to rise significantly from 2024 to 2028. In 2023, imports stood at an estimated threshold below the forecasted values beginning in 2024, underpinning a steady growth trajectory. The anticipated increase from 2024 to 2028 reflects a robust annual growth trend with year-on-year growth rates suggesting a healthy rise in demand or strategic import planning. The compound annual growth rate (CAGR) over this period indicates a strong upward trajectory.
Future trends to watch for include potential shifts in China's domestic vaccine production capabilities, which might affect import dependency, and broader geopolitical or economic changes that could impact international trade dynamics. Monitoring developments in healthcare policies and technology advancements in vaccine formulation will also be crucial.
